Christopher Suhler

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised Decagon, an innovator in conversational artificial intelligence agents for customer experience, on its $131 million Series C financing round, pushing its total funding to $231 million.

Cooley advised Logik.ai, an industry leader offering a modern, artificial intelligence (AI)-powered, composable configure, price and quote solution, on its acquisition by ServiceNow (NYSE: NOW), the AI platform for business transformation.

Cooley advised Chemistry, an early-stage venture firm that leads investments in standout software companies at the Seed and Series A stages, on its $350 million debut fund, Chemistry Fund 1.

Cooley advised RTZ Systems, an information technology and services company, on its acquisition by CollabriOS Health, a new entity formed by Assured Healthcare Partners that brings together a suite of integrated technology infrastructure, including electronic health records, third-party administrator financial services, and care coordination solutions designed to help Programs of All-Inclusive Care for the Elderly (PACE) optimize workflows, streamline business processes and enhance overall center operations.